The huminsulin range of products is indicated for the treatment of type 1 and type 2 diabetes mellitus to improve blood sugar control in both adults and childre
The Lilly Medicine Foundry is set to drive innovation in drug production and make medicines for clinical trials
Lilly will license certain baricitinib manufacturing know-how to enable EVA Pharma to manufacture and supply treatment for various immunological diseases
This partnership aims to accelerate research and development into innovative treatments and, if successful, will generate milestones and royalties
Acquisition to expand Lilly's immunology pipeline with oral integrin therapies
SYNERGY-NASH results were presented at the European Association for the Study of the Liver Congress 2024 and simultaneously published in The New England Journal of Medicine
Ashkenazi will continue to serve at full capacity in her role and as a member of Lilly's Executive Committee through July 2024
Seymour is recognized as one of the foremost quality leaders in the pharmaceutical industry
Seymour is recognized as one of the foremost quality leaders in the pharmaceutical industry
Largest investment in active pharmaceutical ingredient manufacturing of synthetic medicines in U.S. history
Subscribe To Our Newsletter & Stay Updated
